Article: Emisphere Technologies: Interim Data Indicates Eligen B12 Oral Formulation Gets Similar Results as B12 Injection.(Clinical report)

Emisphere Technologies, Inc. has announced that interim data from an ongoing study demonstrated its high-dose oral Eligen B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency.

In a release, the Company noted:

Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have currently taken Eligen B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken.

As part of an interim analysis in this randomized, multi-center study, levels of serum B12, active B12, homocysteine and methyl malonic acid were measured on day 15, at ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!